[{"id":"5d40cbb9-9b7d-4caa-a02e-60a23ee29960","acronym":"The 3P-C Trial","url":"https://clinicaltrials.gov/study/NCT04207944","created_at":"2021-07-05T17:27:20.942Z","updated_at":"2024-07-02T16:35:01.346Z","phase":"Phase 2","brief_title":"The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)","source_id_and_acronym":"NCT04207944 - The 3P-C Trial","lead_sponsor":"Duke University","biomarkers":" GNAS • MMP9","pipe":" | ","alterations":" GNAS mutation","tags":["GNAS • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAS mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-05-23"},{"id":"2596d054-c026-44f9-97aa-9b8cded00810","acronym":"","url":"https://clinicaltrials.gov/study/NCT05841550","created_at":"2023-05-03T15:04:56.218Z","updated_at":"2024-07-02T16:35:30.425Z","phase":"Phase 1/2","brief_title":"The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma","source_id_and_acronym":"NCT05841550","lead_sponsor":"Oslo University Hospital","biomarkers":" KRAS • NRAS • IFNG • TNFA • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • IFNG • TNFA • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Capoxigem (apricoxib) • TG01 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 05/19/2035","study_completion_date":" 05/19/2035","last_update_posted":"2023-11-03"},{"id":"16375f35-57e8-4891-ab8d-34d2a7ad1e54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495894","created_at":"2021-01-18T21:35:34.159Z","updated_at":"2024-07-02T16:35:32.024Z","phase":"Phase 1","brief_title":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","source_id_and_acronym":"NCT04495894","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-24"},{"id":"8c0cad02-2897-4ee2-8f3a-675298ec5be6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00090974","created_at":"2021-01-18T00:16:30.416Z","updated_at":"2024-07-02T16:35:45.534Z","phase":"Phase 3","brief_title":"Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer","source_id_and_acronym":"NCT00090974","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • exemestane • celecoxib oral"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 01/26/2005","start_date":" 01/26/2005","primary_txt":" Primary completion: 01/30/2013","primary_completion_date":" 01/30/2013","study_txt":" Completion: 01/30/2013","study_completion_date":" 01/30/2013","last_update_posted":"2023-06-15"},{"id":"cb93f92e-b678-4306-ae62-affa614ff973","acronym":"","url":"https://clinicaltrials.gov/study/NCT02552394","created_at":"2021-01-18T12:21:08.158Z","updated_at":"2024-07-02T16:35:51.280Z","phase":"Phase 1","brief_title":"J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts","source_id_and_acronym":"NCT02552394","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 11/14/2019","primary_completion_date":" 11/14/2019","study_txt":" Completion: 01/03/2021","study_completion_date":" 01/03/2021","last_update_posted":"2023-04-06"},{"id":"c1a1af83-90fc-451d-8fcd-427d757b2ead","acronym":"","url":"https://clinicaltrials.gov/study/NCT04930354","created_at":"2021-06-18T23:52:44.282Z","updated_at":"2024-07-02T16:35:55.340Z","phase":"Phase 1","brief_title":"ECP-1014 Treatment for Patients With Solid Tumor Cancers","source_id_and_acronym":"NCT04930354","lead_sponsor":"Euclises Pharmaceuticals, Inc.","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ECP-1014"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-02-16"},{"id":"6ca52df8-638a-4323-b022-d68d886a646a","acronym":"ERLO-XIB","url":"https://clinicaltrials.gov/study/NCT02748707","created_at":"2021-01-18T13:27:59.774Z","updated_at":"2024-07-02T16:36:11.256Z","phase":"Phase 2","brief_title":"Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study","source_id_and_acronym":"NCT02748707 - ERLO-XIB","lead_sponsor":"Tata Memorial Hospital","biomarkers":" EGFR • TP53","pipe":"","alterations":" ","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/18/2015","start_date":" 08/18/2015","primary_txt":" Primary completion: 02/12/2018","primary_completion_date":" 02/12/2018","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-04-28"},{"id":"d71e2201-49b6-4836-82b8-2c176d8657e0","acronym":"HFS","url":"https://clinicaltrials.gov/study/NCT05327751","created_at":"2022-04-14T12:54:02.941Z","updated_at":"2024-07-02T16:36:12.736Z","phase":"Phase 3","brief_title":"Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05327751 - HFS","lead_sponsor":"Tanta University","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-04-14"},{"id":"6ed25a2c-816b-431f-9aca-3d4920a47247","acronym":"COLA","url":"https://clinicaltrials.gov/study/NCT02484664","created_at":"2021-01-18T11:58:12.435Z","updated_at":"2024-07-02T16:36:18.233Z","phase":"Phase 2","brief_title":"COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC","source_id_and_acronym":"NCT02484664 - COLA","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 11/19/2018","primary_completion_date":" 11/19/2018","study_txt":" Completion: 11/19/2018","study_completion_date":" 11/19/2018","last_update_posted":"2022-01-20"},{"id":"f2ccb155-4831-4f65-afea-0623ec426e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299195","created_at":"2021-02-24T12:52:38.575Z","updated_at":"2024-07-02T16:36:38.469Z","phase":"","brief_title":"A Randomized Study of Sulindac in Oral Premalignant Lesions","source_id_and_acronym":"NCT00299195","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/23/2006","start_date":" 02/23/2006","primary_txt":" Primary completion: 01/06/2020","primary_completion_date":" 01/06/2020","study_txt":" Completion: 01/06/2020","study_completion_date":" 01/06/2020","last_update_posted":"2020-11-19"},{"id":"eae090bd-dc86-4985-9c25-950f6174910f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00033371","created_at":"2021-01-18T00:01:08.058Z","updated_at":"2024-07-02T16:36:40.614Z","phase":"Phase 2","brief_title":"Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT00033371","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 205","initiation":"Initiation: 12/13/2001","start_date":" 12/13/2001","primary_txt":" Primary completion: 02/24/2009","primary_completion_date":" 02/24/2009","study_txt":" Completion: 03/24/2009","study_completion_date":" 03/24/2009","last_update_posted":"2020-09-29"},{"id":"e94bc33f-4b68-4cea-9cad-25269ea1d5ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT00020878","created_at":"2021-02-11T09:52:26.698Z","updated_at":"2024-07-02T16:36:42.420Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers","source_id_and_acronym":"NCT00020878","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 03/01/2001","start_date":" 03/01/2001","primary_txt":" Primary completion: 11/01/2002","primary_completion_date":" 11/01/2002","study_txt":" Completion: 05/01/2009","study_completion_date":" 05/01/2009","last_update_posted":"2020-08-03"},{"id":"fa835ecb-676b-4c26-84a4-e3e084a094f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003625","created_at":"2021-01-18T09:08:59.533Z","updated_at":"2024-07-02T16:36:44.958Z","phase":"Phase 2","brief_title":"Meloxicam vs Placebo for Mobilization","source_id_and_acronym":"NCT02003625","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2020-05-18"},{"id":"6d4ff3f4-1d80-440a-9e46-70e91aa31170","acronym":"CELEBRIDO","url":"https://clinicaltrials.gov/study/NCT03896113","created_at":"2021-01-18T19:11:21.793Z","updated_at":"2024-07-02T16:36:51.476Z","phase":"Phase 2","brief_title":"Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma","source_id_and_acronym":"NCT03896113 - CELEBRIDO","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" CD8 • IDO1 • CD4","pipe":" | ","alterations":" IDO1 expression","tags":["CD8 • IDO1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-01-10"},{"id":"74313848-6b6f-4543-9ddd-07a7c1b55596","acronym":"","url":"https://clinicaltrials.gov/study/NCT03185871","created_at":"2021-01-18T15:42:31.720Z","updated_at":"2024-07-02T16:36:53.683Z","phase":"Phase 2","brief_title":"Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses","source_id_and_acronym":"NCT03185871","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" PGR • CD163 • SDC1 • PTGS2 • VIM • CD68","pipe":" | ","alterations":" PGR positive • PTGS2 expression • SDC1 expression","tags":["PGR • CD163 • SDC1 • PTGS2 • VIM • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • PTGS2 expression • SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 10/10/2018","primary_completion_date":" 10/10/2018","study_txt":" Completion: 10/10/2018","study_completion_date":" 10/10/2018","last_update_posted":"2019-11-15"},{"id":"4639e2af-824c-45eb-8c5b-38fa16797344","acronym":"","url":"https://clinicaltrials.gov/study/NCT00685568","created_at":"2021-01-18T02:33:46.130Z","updated_at":"2024-07-02T16:37:05.500Z","phase":"Phase 1","brief_title":"Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis","source_id_and_acronym":"NCT00685568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/21/2002","start_date":" 11/21/2002","primary_txt":" Primary completion: 04/21/2006","primary_completion_date":" 04/21/2006","study_txt":" Completion: 04/21/2006","study_completion_date":" 04/21/2006","last_update_posted":"2018-11-07"},{"id":"8ecb7624-1e34-46a2-8e81-e407b465fc51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052611","created_at":"2021-01-18T00:05:52.353Z","updated_at":"2024-07-02T16:37:12.672Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia","source_id_and_acronym":"NCT00052611","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1","pipe":" | ","alterations":" BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression","tags":["BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 03/01/2005","primary_completion_date":" 03/01/2005","study_txt":" Completion: 03/01/2005","study_completion_date":" 03/01/2005","last_update_posted":"2018-03-29"},{"id":"be33c6f4-5193-44de-8e6d-d515da4df4c4","acronym":"UAB0040","url":"https://clinicaltrials.gov/study/NCT00582660","created_at":"2021-01-18T02:08:40.906Z","updated_at":"2024-07-02T16:37:21.014Z","phase":"Phase 2b","brief_title":"Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib","source_id_and_acronym":"NCT00582660 - UAB0040","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CTNNB1 • CEACAM5 • ALOX15","pipe":"","alterations":" ","tags":["CTNNB1 • CEACAM5 • ALOX15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2001","start_date":" 12/01/2001","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 06/01/2008","study_completion_date":" 06/01/2008","last_update_posted":"2017-06-15"},{"id":"8f0d03c5-23ac-4cf6-8679-f7ad9080d8a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00335504","created_at":"2021-01-18T01:09:30.358Z","updated_at":"2024-07-02T16:37:25.648Z","phase":"Phase 2","brief_title":"Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia","source_id_and_acronym":"NCT00335504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 03/01/2006","start_date":" 03/01/2006","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":" Completion: 04/01/2009","study_completion_date":" 04/01/2009","last_update_posted":"2017-02-15"},{"id":"c1fb6dd6-1a73-44a6-8b11-985568b3887f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00056082","created_at":"2021-01-18T00:06:51.099Z","updated_at":"2024-07-02T16:37:25.659Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women","source_id_and_acronym":"NCT00056082","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ER negative","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 01/01/2003","start_date":" 01/01/2003","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2017-02-15"},{"id":"8d0f86f7-c4c8-468d-be6d-e8ccc24dc6cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070057","created_at":"2024-01-06T23:17:02.166Z","updated_at":"2024-07-02T16:37:26.857Z","phase":"Phase 1","brief_title":"Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer","source_id_and_acronym":"NCT00070057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1 • MAPK3","pipe":"","alterations":" ","tags":["MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2016-12-29"},{"id":"3d38fdc0-92a6-41ab-9768-ebd18f75b59e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073073","created_at":"2021-01-18T00:11:27.292Z","updated_at":"2024-07-02T16:37:32.131Z","phase":"Phase 2","brief_title":"Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer","source_id_and_acronym":"NCT00073073","lead_sponsor":"Georgetown University","biomarkers":" BRCA1 • BRCA2 • PCNA • TFF1 • LEP","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PCNA expression","tags":["BRCA1 • BRCA2 • PCNA • TFF1 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2016-05-17"}]